ESSA Pharma Inc. (EPIX)

Market Cap	71.02M
Revenue (ttm)	n/a
Net Income (ttm)	-28.54M
Shares Out	44.39M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	245,287
Open	1.580
Previous Close	1.600
Day's Range	1.580 - 1.640
52-Week Range	1.400 - 11.670
Beta	1.62
Analysts	Hold
Price Target	2.00 (+25.0%)
Earnings Date	Dec 17, 2024

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: EPIX
• Website: https://www.essapharma.com

Analyst Forecast

According to 3 analysts, the average rating for EPIX stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 25.00% from the latest price.

Price Target

$2.0

(25.00% upside)

Analyst Consensus: Hold